Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer

Background: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosin...

Descripción completa

Detalles Bibliográficos
Autores: Delgado-García, Mercedes, Weynand, Birgit, Gómez-Izquierdo, Lourdes, Hernández, María José, Blanco, Ángela María, Varela, Mar, Matias-Guiu, Xavier, Nadal, Ernest, Márquez-Lobo, Bélgica, Alarcão, Ana, de Álava, Enrique, Biscuola, Michele
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/70715
Acceso en línea:https://doi.org/10.1186/s12885-020-6697-7
http://hdl.handle.net/10459.1/70715
Access Level:acceso abierto
Palabra clave:Non-small-cell lung carcinoma
EGFR
Mutations
id ES_b765e08cfc4ee664cd4e8395a0bb7a21
oai_identifier_str oai:recercat.cat:10459.1/70715
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancerDelgado-García, MercedesWeynand, BirgitGómez-Izquierdo, LourdesHernández, María JoséBlanco, Ángela MaríaVarela, MarMatias-Guiu, XavierNadal, ErnestMárquez-Lobo, BélgicaAlarcão, Anade Álava, EnriqueBiscuola, MicheleNon-small-cell lung carcinomaEGFRMutationsBackground: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results: The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracySupported by each clinical center. Biocartis provided free-of-charge Idylla™ EGFR Mutation Test cartridgesBMC2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1186/s12885-020-6697-7http://hdl.handle.net/10459.1/70715reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.1186/s12885-020-6697-7BMC Cancer, 2020, vol. 20cc-by (c) Delgado-García et al., 2020info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/707152026-05-29T05:05:01Z
dc.title.none.fl_str_mv Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
title Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
spellingShingle Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
Delgado-García, Mercedes
Non-small-cell lung carcinoma
EGFR
Mutations
title_short Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
title_full Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
title_fullStr Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
title_full_unstemmed Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
title_sort Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
dc.creator.none.fl_str_mv Delgado-García, Mercedes
Weynand, Birgit
Gómez-Izquierdo, Lourdes
Hernández, María José
Blanco, Ángela María
Varela, Mar
Matias-Guiu, Xavier
Nadal, Ernest
Márquez-Lobo, Bélgica
Alarcão, Ana
de Álava, Enrique
Biscuola, Michele
author Delgado-García, Mercedes
author_facet Delgado-García, Mercedes
Weynand, Birgit
Gómez-Izquierdo, Lourdes
Hernández, María José
Blanco, Ángela María
Varela, Mar
Matias-Guiu, Xavier
Nadal, Ernest
Márquez-Lobo, Bélgica
Alarcão, Ana
de Álava, Enrique
Biscuola, Michele
author_role author
author2 Weynand, Birgit
Gómez-Izquierdo, Lourdes
Hernández, María José
Blanco, Ángela María
Varela, Mar
Matias-Guiu, Xavier
Nadal, Ernest
Márquez-Lobo, Bélgica
Alarcão, Ana
de Álava, Enrique
Biscuola, Michele
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Non-small-cell lung carcinoma
EGFR
Mutations
topic Non-small-cell lung carcinoma
EGFR
Mutations
description Background: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results: The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1186/s12885-020-6697-7
http://hdl.handle.net/10459.1/70715
url https://doi.org/10.1186/s12885-020-6697-7
http://hdl.handle.net/10459.1/70715
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1186/s12885-020-6697-7
BMC Cancer, 2020, vol. 20
dc.rights.none.fl_str_mv cc-by (c) Delgado-García et al., 2020
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Delgado-García et al., 2020
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417526102851584
score 15,812429